Park Jumin, Ross Alyson, Klagholz Stephen D, Bevans Margaret F
1 National Institutes of Health Clinical Center, Bethesda, MD, USA.
Biol Res Nurs. 2018 May;20(3):300-311. doi: 10.1177/1099800417740970. Epub 2017 Nov 12.
Biomarkers can be used as prognostic, predictive, or monitoring indicators of an associated outcome. The purpose of this review was to provide a comprehensive summary of the research examining the use of biomarkers as surrogate end points for clinical outcomes in family caregivers for cancer patients, identify gaps, and make recommendations for future research.
A scoping review, a process of mapping the existing literature, was conducted. Studies comparing biomarkers across caregivers and controls and/or examining relationships between biomarkers and psychological health were reviewed.
The studies ( N = 18) of caregivers for cancer patients who were identified used biomarkers to predict outcomes ( n = 13) and to monitor the efficacy of interventions ( n = 6). Biomarkers were divided into two categories based on physiological systems involved: (1) neuroendocrine function (sympathetic-adrenal-medullary axis activity, hypothalamic-pituitary-adrenal axis activity) and (2) immune function. Predictive biomarkers were sensitive to differences between caregivers and controls. The biomarkers were used to evaluate outcomes frequently associated with stress, depression, and anxiety. Cortisol was the biomarker most commonly measured to monitor the efficacy of interventions.
Biomarkers are most commonly incorporated into caregiver studies to predict group membership and psychological health. Neuroendocrine biomarkers, specifically cortisol, are most frequently assessed. Future research should include biomarkers of other physiologic functions (e.g., cardiovascular function, cognitive dysfunction, and cell aging) and those that serve as multisystem indicators. Expanding the scientific study of biomarkers will contribute to our understanding of the mechanisms through which stress may influence caregiver health.
生物标志物可作为相关结局的预后、预测或监测指标。本综述的目的是全面总结关于将生物标志物用作癌症患者家庭照护者临床结局替代终点的研究,找出差距,并为未来研究提出建议。
进行了一项范围综述,即对现有文献进行梳理的过程。对比较照护者与对照组生物标志物以及/或者研究生物标志物与心理健康之间关系的研究进行了综述。
所纳入的针对癌症患者照护者的研究(N = 18项)中,生物标志物被用于预测结局(n = 13项)以及监测干预效果(n = 6项)。基于所涉及的生理系统,生物标志物被分为两类:(1)神经内分泌功能(交感-肾上腺-髓质轴活动、下丘脑-垂体-肾上腺轴活动)和(2)免疫功能。预测性生物标志物对照护者与对照组之间的差异敏感。这些生物标志物被用于评估经常与压力、抑郁和焦虑相关的结局。皮质醇是最常用于监测干预效果的生物标志物。
生物标志物最常被纳入照护者研究以预测分组和心理健康。神经内分泌生物标志物,尤其是皮质醇,是最常被评估的。未来研究应纳入其他生理功能的生物标志物(例如心血管功能、认知功能障碍和细胞衰老)以及那些作为多系统指标的生物标志物。扩展生物标志物的科学研究将有助于我们理解压力可能影响照护者健康的机制。